Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00826449 · ClinicalTrials.gov registry record · Phase 1
Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 53
- Enrollment target
NCT00826449: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00826449 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 53 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00826449, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 53 participants
- Enrollment target
Study Summary
The goal of the Phase I portion of this study is to find the highest tolerable dose of the combination of dasatinib and erlotinib hydrochloride that can be given to patients with advanced solid tumors. The goal of the Phase II portion of this study is to learn if this combination is effective when given to patients with non-small cell lung cancer. The safety of this combination will be studied in both phases.
Interventions
- DRUG Dasatinib
- DRUG Erlotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2009-02 |
| Est. Completion | 2014-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00826449
The ClinicalTrials.gov registry entry for NCT00826449 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dasatinib is the first listed.
NCT00826449 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00826449 about?
NCT00826449 is a clinical study titled "Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)". The goal of the Phase I portion of this study is to find the highest tolerable dose of the combination of dasatinib and erlotinib hydrochloride that can be given to patients with advanced solid tumors. The goal of the Phase II portion of this study is to learn if this combination is effective when ...
What is the current status of trial NCT00826449?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 53 participants. The study started on 2009-02. Estimated completion is 2014-06.
What interventions are being tested in trial NCT00826449?
The interventions under investigation include: Dasatinib (DRUG), Erlotinib (DRUG).
Who is sponsoring clinical trial NCT00826449?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.